Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HEC Group
Dongguan, Guangdong, China
- Ownership
- Private
- Employees
- ~20000
- Development stage
- Other
01
Overview
HEC Group is the world's largest producer of macrolide antibiotics (notably erythromycin and its derivatives), and a leader in oseltamivir (for influenza) in China. Its portfolio includes commercialized and approved medicines for influenza, diabetes, cardiovascular, endocrine and metabolic diseases. It is FDA and EDQM approved for both APIs and finished dosages[5][8][12].
- Therapeutic areas
- EndocrinologyCardiovascularInfectious DiseasesMetabolic Disorders
- Modalities
- Small moleculeBiologicActive Pharmaceutical IngredientDosage form manufacturing
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on HEC Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEC Group.